Adalimumab as a cause of kidney injury in patients with Crohn's disease

Krzysztof Skoczyński; Jan Koziej; Sylwia Szymańska; Łukasz Obrycki; Ryszard Grenda; Mieczysław Litwin

doi:10.1007/s00467-024-06338-0

Adalimumab as a cause of kidney injury in patients with Crohn's disease

Pediatr Nephrol. 2024 Mar 8. doi: 10.1007/s00467-024-06338-0. Online ahead of print.

Authors

Krzysztof Skoczyński^{1

2}, Jan Koziej^{1

2}, Sylwia Szymańska³, Łukasz Obrycki¹, Ryszard Grenda¹, Mieczysław Litwin^{4

5}

Affiliations

¹ Department of Nephrology, Kidney Transplantation and Hypertension, The Children`s Memorial Health Institute, Warsaw, Poland.
² Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszyński University, Warsaw, Poland.
³ Department of Pathology, The Children`s Memorial Health Institute, Warsaw, Poland.
⁴ Department of Nephrology, Kidney Transplantation and Hypertension, The Children`s Memorial Health Institute, Warsaw, Poland. m.litwin@ipczd.pl.
⁵ Chair of Pediatric Nephrology, The Center of Continuing Medical Education, Warsaw, Poland. m.litwin@ipczd.pl.

PMID: 38456916
DOI: 10.1007/s00467-024-06338-0

Abstract

Introduction: Adalimumab (ADM) is a recombinant human monoclonal antibody (anti-TNFα) used to treat inflammatory bowel diseases. It can cause kidney injury (KI).

Case diagnosis/treatment: We describe two pediatric patients with Crohn's disease (CD) in whom ADM therapy was associated with kidney injury (KI). The drug was discontinued in both cases. For the first patient, changes were irreversible despite intensive glucocorticosteroid (GCS) therapy. For the second patient, discontinuation of ADM led to an improvement in kidney function.

Conclusions: Due to the risk of KI in patients undergoing ADM therapy, careful assessment of kidney function and early specialist referral are required. Timely withdrawal of ADM can significantly reduce kidney damage, but in some cases, the kidney damage can be irreversible.

Keywords: Adalimumab; Crohn’s disease; Drug reaction; Kidney injury.